Met Life Investment Management, LLC Coherus Bio Sciences, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

35 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$1.58 - $2.51 $13,512 - $21,465
8,552 Added 15.79%
62,706 $108,000
Q1 2024

May 14, 2024
BUY
$2.02 - $3.14 $109,391 - $170,043
54,154 New
54,154 $129,000
Q3 2023

May 09, 2024
BUY
$3.74 - $5.45 $53,253 - $77,602
14,239 Added 36.61%
53,130 $198,000
Q3 2023

Apr 29, 2024
BUY
$3.74 - $5.45 $53,253 - $77,602
14,239 Added 36.61%
53,130 $198,000
Q3 2023

Nov 14, 2023
BUY
$3.74 - $5.45 $53,253 - $77,602
14,239 Added 36.61%
53,130 $198,000
Q2 2023

Apr 29, 2024
BUY
$3.79 - $8.3 $147,396 - $322,795
38,891 New
38,891 $166,000
Q2 2023

Aug 10, 2023
BUY
$3.79 - $8.3 $147,396 - $322,795
38,891 New
38,891 $166,000
Q1 2023

May 09, 2024
BUY
$5.89 - $10.52 $229,067 - $409,133
38,891 New
38,891 $266 Million
Q4 2022

Jun 14, 2023
BUY
$5.69 - $10.07 $221,289 - $391,632
38,891 New
38,891 $308,000
Q3 2022

May 10, 2024
BUY
$7.17 - $13.87 $28,701 - $55,521
4,003 Added 11.47%
38,891 $373,000
Q3 2022

Jun 14, 2023
BUY
$7.17 - $13.87 $278,848 - $539,418
38,891 New
38,891 $373,000
Q3 2022

Mar 22, 2023
BUY
$7.17 - $13.87 $28,701 - $55,521
4,003 Added 11.47%
38,891 $373,000
Q3 2022

Nov 14, 2022
BUY
$7.17 - $13.87 $28,701 - $55,521
4,003 Added 11.47%
38,891 $374,000
Q2 2022

Jun 20, 2023
BUY
$5.86 - $13.23 $204,443 - $461,568
34,888 New
34,888 $252,000
Q1 2022

May 10, 2024
BUY
$10.92 - $16.41 $380,976 - $572,512
34,888 New
34,888 $450,000
Q1 2022

Jun 20, 2023
BUY
$10.92 - $16.41 $380,976 - $572,512
34,888 New
34,888 $450,000
Q1 2022

Mar 22, 2023
BUY
$10.92 - $16.41 $148,118 - $222,585
13,564 Added 63.61%
34,888 $450,000
Q1 2022

May 12, 2022
BUY
$10.92 - $16.41 $148,118 - $222,585
13,564 Added 63.61%
34,888 $450,000
Q4 2021

Jun 21, 2023
BUY
$15.81 - $18.99 $337,132 - $404,942
21,324 New
21,324 $340,000
Q3 2021

Jun 21, 2023
BUY
$12.68 - $17.79 $270,388 - $379,353
21,324 New
21,324 $342,000
Q1 2021

May 17, 2024
SELL
$14.42 - $21.39 $473,408 - $702,233
-32,830 Reduced 60.62%
21,324 $311,000
Q1 2021

Jun 26, 2023
BUY
$14.42 - $21.39 $307,492 - $456,120
21,324 New
21,324 $312 Million
Q1 2021

Mar 22, 2023
SELL
$14.42 - $21.39 $253,316 - $375,758
-17,567 Reduced 45.17%
21,324 $311,000
Q1 2021

May 14, 2021
BUY
$14.42 - $21.39 $307,492 - $456,120
21,324 New
21,324 $312,000
Q4 2020

Jun 22, 2023
BUY
$16.56 - $18.94 $470,403 - $538,009
28,406 New
28,406 $494 Million
Q3 2020

Jun 26, 2023
BUY
$17.41 - $19.89 $494,548 - $564,995
28,406 New
28,406 $521 Million
Q2 2020

May 24, 2024
SELL
$14.43 - $19.16 $371,543 - $493,331
-25,748 Reduced 47.55%
28,406 $507 Million
Q2 2020

Jun 26, 2023
BUY
$14.43 - $19.16 $409,898 - $544,258
28,406 New
28,406 $507 Million
Q1 2020

Jul 12, 2023
BUY
$11.67 - $22.53 $331,498 - $639,987
28,406 New
28,406 $461 Million
Q4 2019

Jul 12, 2023
BUY
$16.33 - $21.37 $463,869 - $607,036
28,406 New
28,406 $511 Million
Q3 2019

Jul 12, 2023
BUY
$16.3 - $23.37 $463,017 - $663,848
28,406 New
28,406 $576 Million
Q2 2019

Jul 12, 2023
BUY
$13.1 - $22.1 $294,383 - $496,631
22,472 New
22,472 $497 Million
Q1 2019

Jul 13, 2023
BUY
$8.38 - $15.5 $188,315 - $348,316
22,472 New
22,472 $307 Million
Q4 2018

Jul 13, 2023
BUY
$8.65 - $16.28 $194,382 - $365,844
22,472 New
22,472 $203 Million
Q3 2018

Jul 13, 2023
BUY
$14.45 - $20.25 $324,720 - $455,058
22,472 New
22,472 $371 Million

Others Institutions Holding CHRS

# of Institutions
135
Shares Held
77.9M
Call Options Held
40.7K
Put Options Held
50.1K
View Full List

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email